Manish Wani, MD
Otolaryngology · Houston, TXNPI 1457348963
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $69,550 of the $100,428 with a category attached, or 69.3%. Stryker accounts for 85.8% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $43,788 and has fallen 97.4% since, to $1,155 in 2025. Among otolaryngology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 250 payments — averaging $401.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$86K
- Checkpoint Surgical, Inc$5K
- Inspire Medical Systems, Inc.$5K
- Intersect ENT, Inc.$843
- Optinose US, Inc.$612
- Aerin Medical Inc.$544
- plus $2K from 15 others
Across 8 payments — averaging $2806.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Stryker$22K
What the payments were for
- Consulting fees$69,55069%
- Travel & lodging$13,13113%
- Food & beverage$12,24012%
- Education$2190%
- Charitable contribution$5,2885%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 148 | $86,181 |
| Checkpoint Surgical, Inc | 1 | $5,288 |
| Inspire Medical Systems, Inc. | 37 | $5,157 |
| Intersect ENT, Inc. | 9 | $843 |
| Optinose US, Inc. | 19 | $612 |
| Aerin Medical Inc. | 8 | $544 |
| Neurent Medical Limited | 4 | $377 |
| Medtronic | 5 | $304 |
| GSK | 2 | $204 |
| Integra Lifesciences Corporation | 2 | $166 |
| Hologic Sales And Service, LLC | 2 | $165 |
| Acclarent, Inc | 2 | $135 |
| Photonicare Inc | 1 | $104 |
| Sanofi | 1 | $92 |
| Olympus America Inc. | 1 | $83 |
| Johnson & Johnson | 2 | $47 |
| Regeneron Healthcare Solutions, Inc. | 1 | $34 |
| Lilly USA, LLC | 2 | $33 |
| Pacira Pharmaceuticals Incorporated | 1 | $23 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| Kerecis Limited | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTELLUS - XPRESS ENT DILATION SYSTEM$50,185
- XPRESS ENT DILATION SYSTEM$23,114
- CLARIFIX CRYOTHERAPY DEVICE$18,319
- LATERA$12,631
- SCOPIS ENT$9,616
- TGS GUIDEWIRE$7,631
- Checkpoint Stimulators$5,288
- ORTHOMAP$2,813
- SHAVER SYSTEM$2,361
- Inspire Upper Airway Stimulation System$2,244
- Inspire$2,126
- ENTELLUS MEDICAL REINFORCED ANESTHESIA NEEDLE$2,063
- N/A$1,125
- PROPEL$593
- AUDION ET DILATION SYSTEM$420
- VIVAER STYLUS$368
- RHINAER STYLUS$368
- SPIROX - LATERA$356
- NEUROMARK System$307
- NEUROMARK Radiofrequency Console$307
How this compares
$100,428 in reported general payments places this provider in the 95th percentile of 729 otolaryngology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ipratropium Bromide | 125 | $4,155 |
| Epinephrine | 18 | $3,140 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 13 | $1,508 |
| Azelastine Hcl | 51 | $1,461 |
| Ofloxacin | 74 | $1,429 |
| Diclofenac Sodium | 46 | $1,081 |
| Naproxen | 115 | $864 |
| Fluticasone Propionate | 52 | $768 |
| Fluocinolone Acetonide Oil | 17 | $691 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 40 | $677 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 39 | $453 |
| Montelukast Sodium | 31 | $452 |
| Prednisolone Acetate | 16 | $451 |
| Chlorzoxazone | 19 | $378 |
| Azithromycin | 77 | $321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USAEpinephrine | $20 | $3,14018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 otolaryngology providers in Texas.
Other otolaryngology in Houston
- Amber LuongHouston$426K
- Arjuna KuperanHouston$348K
- Ron KarniHouston$317K
- Martin CitardiHouston$245K
- Michael KaplanHouston$202K
- Masayoshi TakashimaHouston$167K
- William YaoHouston$154K
- Andrew HuangHouston$137K
- Shane PahlavanHouston$95K
- Omar AhmedHouston$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.